

**COPY**



UNITED STATES PATENT AND TRADEMARK OFFICE


COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov



APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/993,756	11/05/2001	Bernard Bailleul	PF-0111-3 CON

CONFIRMATION NO. 9899

FORMALITIES LETTER



\*OC000000007236909\*

MYCITE GENOMICS, INC.  
PATENT DEPARTMENT  
3160 Porter Drive  
Palo Alto, CA 94304

Date Mailed: 12/28/2001

**NOTICE TO FILE CORRECTED APPLICATION PAPERS**

***Filing Date Granted***

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
  - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
  - drawings submitted to the Office are not electronically reproducible. Drawing sheets must be submitted on paper which is flexible, strong, white, smooth, non-shiny, and durable (see 37 CFR 1.84(e));
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

---

*A copy of this notice MUST be returned with the reply.*



---

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

Box Seq 0300  
Docket No.: PF-0111-3 CON

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202  
on February 20, 2002

By: Debbie Ellis Printed name: Debbie Ellis

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bailleul et al.

Title: HUMAN LEPTIN RECEPTOR GENE-RELATED PROTEIN

Serial No.: 09/993,756

Filing Date: November 05, 2001

Examiner: To Be Assigned

Group Art Unit: 1646

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

RESPONSE TO NOTICE TO FILE  
CORRECTED APPLICATION PAPERS

Sir:

In response to the "Notice to File Corrected Application Papers - Filing Date Granted" mailed by the United States Patent and Trademark Office on December 28, 2001, Applicants submit the following documents to complete the filing for the above-identified patent application:

1. Copy of Notice to File Corrected Application Papers - Filing Date Granted (3 pp.);
2. Response to Notice to File Corrected Application Papers (2 pp.);
3. Submission of Formal Drawings (2 pp.);
4. Eleven (11) sheets of Formal Drawings (Figs. 1A, 1B, 1C, 2, 3, 4, 5, 6, 7, 8 and 9);
5. Submission of Substitute Computer-readable Diskette copy of Sequence Listing (1 pg.);
6. One (1) substitute computer-readable diskette copy of Sequence Listing as filed;
7. Preliminary Amendment (6 pp.); and
8. Return postcard.

No fee is believed to be due with this communication, but if the Patent Office determines that additional fees are due or that an excess fee has been paid, the Patent Office is authorized to debit or

09/993,756

**Docket No.: PF-0111-3 CON**

credit (respectively) **Deposit Account No. 09-0108.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

*Michelle M. Stempien*

Michelle M. Stempien

Reg. No. 41,327

Direct Dial Telephone: (650) 843-7219

Date: 20 February 2002

3160 Porter Drive  
Palo Alto, CA 94304  
Tel: 650-855-0555  
Fax: 650-849-8886

Docket No.: PF-0111-3 CON

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed to:  
U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202  
on February 20, 2002

#3

By: Debbie Ellis

Printed name: Debbie Ellis



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bailleul et al.

Title: HUMAN LEPTIN RECEPTOR GENE-RELATED PROTEIN

Serial No.: 09/993,756

Filing Date: November 05, 2001

Examiner: To Be Assigned

Group Art Unit: 1646

### Official Draftsman

U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

### SUBMISSION OF FORMAL DRAWINGS

Sir:

Transmitted herewith are Figure(s) 1A, 1B, 1C, 2, 3, 4, 5, 6, 7, 8 and 9, as eleven (11) sheets of formal drawings for this application. Each sheet of drawing indicates the identifying indicia suggested in 37 CFR Section 1.84(c) on the top of the drawing.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**.

$$\frac{d^2}{dt^2} \left( \frac{\partial L}{\partial \dot{x}} \right) = \frac{\partial L}{\partial x}, \quad \frac{d^2}{dt^2} \left( \frac{\partial L}{\partial \dot{y}} \right) = \frac{\partial L}{\partial y}, \quad \frac{d^2}{dt^2} \left( \frac{\partial L}{\partial \dot{z}} \right) = \frac{\partial L}{\partial z}$$

**Docket No.: PF-0111-3 CON**

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,  
 INCYTE GENOMICS, INC.

Date: 20 February 2002

Michelle M. Stempin

Michelle M. Stempien

Reg. No. 41,327

Direct Dial Telephone: (650) 843-7219

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166